Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.600
-0.020 (-0.76%)
May 18, 2026, 10:31 AM EDT - Market open
Editas Medicine Employees
Editas Medicine had 87 employees as of December 31, 2025. The number of employees decreased by 159 or -64.63% compared to the previous year.
Employees
87
Change (1Y)
-159
Growth (1Y)
-64.63%
Revenue / Employee
$444,747
Profits / Employee
-$1,252,345
Market Cap
254.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 87 | -159 | -64.63% |
| Dec 31, 2024 | 246 | -19 | -7.17% |
| Dec 31, 2023 | 265 | 39 | 17.26% |
| Dec 31, 2022 | 226 | -38 | -14.39% |
| Dec 31, 2021 | 264 | 29 | 12.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Coherus Oncology | 145 |
| Tonix Pharmaceuticals Holding | 142 |
| AC Immune | 122 |
| Alector | 103 |
| SAB Biotherapeutics | 86 |
| Compugen | 75 |
| ALX Oncology Holdings | 43 |
EDIT News
- 4 days ago - Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia - TheFly
- 4 days ago - Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting - GlobeNewsWire
- 13 days ago - Editas Medicine reports Q1 EPS (26c), consensus (24c) - TheFly
- 13 days ago - Editas Medicine Announces First Quarter 2026 Results and Business Updates - GlobeNewsWire
- 20 days ago - Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - GlobeNewsWire
- 5 weeks ago - Editas Medicine price target raised to $15 from $13 at Evercore ISI - TheFly
- 7 weeks ago - Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents - TheFly
- 7 weeks ago - Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - GlobeNewsWire